In the preceding paper (1) it was pointed out that the administration of sodium salicylate to man induces a number of changes suggestive of thyrotoxicosis. There is an elevated basal metabolic rate (BMR), negative nitrogen balance, a fall in the cholesterol level of the hypothyroid subject, and an accelerated fractional disappearance rate of labeled thyroxine from the circulation. Paradoxically, salicylate-induced hypermetabolism is not accompanied by certain of the clinical characteristics of hyperthyroidism and is associated with depressed thyroid function as measured by thyroidal radioiodine uptake and clearance, or the serum protein bound iodine (PBI) concentration. The salicylate level in the serum of such patients is not high enough to interfere with in vitro iodine metabolism in rat thyroid slices, and in acute experiments in rats no depression of the iodide concentrating mechanism can be demonstrated at blood salicylate levels comparable to those attained in the above patients (1). Similar findings had previously been recorded in rats and in man treated with 2,4-dinitrophenol (2-4). It was subsequently shown (5) that this thyroid depression produced by 2,4-dinitrophenol probably resulted from inhibition at a pituitary or higher level.
In the preceding paper (1) it was pointed out that the administration of sodium salicylate to man induces a number of changes suggestive of thyrotoxicosis. There is an elevated basal metabolic rate (BMR), negative nitrogen balance, a fall in the cholesterol level of the hypothyroid subject, and an accelerated fractional disappearance rate of labeled thyroxine from the circulation. Paradoxically, salicylate-induced hypermetabolism is not accompanied by certain of the clinical characteristics of hyperthyroidism and is associated with depressed thyroid function as measured by thyroidal radioiodine uptake and clearance, or the serum protein bound iodine (PBI) concentration. The salicylate level in the serum of such patients is not high enough to interfere with in vitro iodine metabolism in rat thyroid slices, and in acute experiments in rats no depression of the iodide concentrating mechanism can be demonstrated at blood salicylate levels comparable to those attained in the above patients (1) . Similar findings had previously been recorded in rats and in man treated with 2,4-dinitrophenol (2) (3) (4) . It was subsequently shown (5) that this thyroid depression produced by 2,4-dinitrophenol probably resulted from inhibition at a pituitary or higher level.
The absence of a direct or immediate effect of salicylates on thyroid tissue, despite marked thyroid depression upon more prolonged exposure to the drug, suggested that this effect may also result from a decrease in thyroid stimulation by thyrotropin (TSH). It is the purpose of this report to suggest a locus of salicylate action and to present some observations on the nature of the inhibitory effect.
MATERIALS AND METHODS
Three euthyroid patients were studied to evaluate the effect of salicylates on the rate of release of radioiodine from the thyroid gland. The technique was similar to that described by Goldsmith, Stanbury, and Brownell (6) . Each patient, while fasting, was given approximately 125 microcuries of radioiodine, and 48 hours later was started on 1-methyl-2-mercaptoimidazole, 30 mg. every six hours, to block the reaccumulation of radioiodine. Counts over the thyroid region were measured each morning with a wide angle scintillation counter. Body background was taken as the thigh count, and the logarithm of the counts remaining in the thyroid after correction for body background and physical decay was plotted against time to determine half-life and rate of release of thyroidal I'.
Thyrotropin' (TSH), dissolved in physiologic saline and injected intramuscularly, was given during salicylate administration to seven patients in a dose of 5 U.S.P. units every 12 hours. In five patients thyrotropin was started immediately after completion of a 2, 5, and 24 hour uptake of I'. Values were corrected for residual counts remaining from any previous experiment. Two other patients received thyrotropin by the same dose schedule while the thyroidal release rate was being studied.
Release of I... from the propylthiouracil-blocked rat thyroid was measured according to the method of Wolff (7) with minor modifications. A rate meter operating off the same detector was used to center the thyroid area prior to counting. The diet used was a modified Remington diet; because rats kept on this diet for prolonged periods showed biological half-lives of thyroidal I.31 of well under 24 hours, rats were fed this diet for only 12 to 16 days prior to the release studies. Each animal served as its own control and the pooled values of each group were plotted semilogarithmically to obtain half-lives of thyroidal 18 * Thyrotropin stimulation (10 U per day) for one day only, whereas given on three successive days to the other patients.
previously described (5) . High dietary levels of sodium salicylate were required to yield measureable effects but these could not be given from the start of the experiment because they led to considerable weight loss. On the other hand, when the sodium salicylate in the diet (Purina Lab Chow) was gradually increased 0.3 per cent per week until a level of 1.2 per cent was reached, no weight loss occurred. The rats were then divided into two groups, one receiving 0.1 per cent propylthiouracil together with the 1.2 per cent sodium salicylate in the diet, the other group, 1.2 per cent sodium salicylate only. Two other groups of rats served as controls-one untreated, the other receiving 0.1 per cent propylthiouracil in the diet. After 11 days on this regimen the thyroids were weighed and prepared for routine histological examination, and the thyroid to plasma (T/S) iodide ratio was determined as described previously (4 
RESULTS AND DISCUSSION
The responsiveness of the salicylate depressed thyroid gland to exogenous thyrotropin is illustrated in Table I . Both the PBI level and P"' uptake showed striking elevations following TSH stimulation in five patients maintained on chronic salicylate therapy.
The administration of sodium salicylate markedly slowed the rate of release of thyroidal I313 (Figures 1 and 2 ), increasing the half-life from 10.7 and 12.4 days, respectively, to one too great for accurate definition. The reduction in release rate was apparent within 36 hours after beginning salicylate; on discontinuation of the drug the slope once again approximated that obtained prior to salicylate treatment ( Figure 1 ). Since it has been demonstrated that one of the main actions of thyrotropin is to stimulate release of hormone from the gland (7), these results suggest that salicylates may in some manner interfere with the action of thyrotropin. That this interference is not due to an inability of the salicylate-depressed gland to respond to thyrotropin has already been noted in Table I . Inhibition of release of thyroidal I"'s by salicylates ( Figure 2 ) (serum concentration, 35 to 51 mg. per 100 ml.) is also readily overcome by exogenous thyrotropic stimulation despite continuation of salicylate administration. Furthermore, the acceleration of release of thyroidal 13", so characteristic of thyrotropic action (7), is not interrupted by salicylate administration sufficient to produce a blood level of 28 to 42 mg. per 100 ml. (Figure 3 ). Since the amount of TSH was greater than the minimal effective dose, it is still possible that a small decrease in sensitivity to TSH resulted from salicylate treatment but could not be demonstrated with the present method.
If the thyrotropin available to the thyroid is diminished by salicylates, this drug might be expected to interfere with goiter formation in propylthiouracil-treated rats. That this did occur is shown in Table II resembled the controls. This variability in the histological picture is reflected in the relatively large standard deviation of the thyroid weights of this group. In contrast, thyroids of propylthiouracil-treated rats showed the usual picture of complete absence of colloid and very tall collumnar epithelium with marked papillary infolding. Rats treated with salicylate and propylthiouracil tended to eat more of the diet than rats kept on propylthiouracil alone. Thus, the intake of goitrogen in the doubly treated group was at least that of the propylthiouracil controls. It is, however, still possible that the rate of metabolism of propylthiouracil was sufficiently increased by salicylate to lead to diminished goitrogenicity. Salicylate treatment alone led to minimal flattening of the epithelium and some pyknosis of the nuclei. The T/S ratio of the salicylate and propylthiouracil-treated rats showed little change from the propylthiouracil group (0.1 < p < 0.2). Results of the studies on the T/S ratio and the histology closely resemble those of the incomplete goiter prevention observed with 2,4-dinitrophenol (5). It is probable that the discrepancy between thyroid weight and the T/S ratio is further evidence that suppression of the TSH level is only partial, since the T/S ratio is known to be more sensitive to slight thyrotropic stimulation (13) . t Because of pretreatment of the salicylate groups, these animals were chosen so that the final weights would be approximately equal.
I Standard deviation of the mean.
Diminished thyrotropic response seemed thus to be implicated, probably at a pituitary or higher level, and we were therefore interested in the report by Pallot and Eberhardt (14) that the C14 of carboxyl-labeled salicylate seemed to be concentrated in the adenohypophysis (tissue/serum ratio equals 0.7 for anterior pituitary, and 0.09 for the other organs). We were able to confirm a "relative" concentration of radioactivity in the anterior pituitary gland when compared to brain, but other organs showed a similar degree of concentration (Table III) . Chromatographic analysis revealed that more than 90 to 95 per cent of the radioactivity of the tissues listed in Table III Figure 2 . Table IV both of these drugs depress the release rate of thyroidal J131. On a dosage basis, y-resorcylate was less active than salicylate; however, strict comparison is not possible, since blood levels comparable to those obtained with sodium salicylate (about 50 mg. per 100 ml.) could never be attained with the diphenolic carboxylic acids, even when these were given every four hours and at three times the daily dose. Maximum -blood levels attained were 2 to 11 mg. per 100 ml. for gentisate and 4 to 18 mg. per 100 ml. for y-resorcylate (measured at 4 hours, i.e., just prior to the next injection). Similar difficulties in maintaining blood levels with gentisic acid have been encountered clinically (15, 16) but lower levels apparently suffice to obtain adequate therapeutic response.
COMMENTS
Thyroxine, dinitrophenol (DNP), and salicylate evoke many similar responses in man or the experimental animal (Table V) . In addition to the similarities noted above, both salicylate and thyroxine accelerate intestinal absorption of glucose (18, 19) , and all three agents can deplete the liver of glycogen (20) (21) (22) and uncouple oxidative phosphorylation (23, 24) . However, the differences of these two phenols from thyroxine are well known, covering a range of effects from an inability to act as substitution therapy in myxedema (25, 26) , to a failure to induce metamorphosis in the tadpole (27) , to an inability to inhibit isolated dehydrogenases in vitro (28) .
Nevertheless, the similarity in the alterations of the indices of thyroid function by these three agents (Table V) has led us to postulate that these changes are the consequence of some common action involving a reduction of the available TSH. What this action is remains to be discovered. The following possibilities have been considered.
It is tempting to correlate thyroid depression with the known ability of salicylate to uncouple oxidative phosphorylation, especially since dinitrophenol and thyroxine (23) are also uncoupling agents. On the basis of the dinitrophenol studies in the rat (4, 5), it had been postulated that the uncoupling action or the metabolic stimulation were possibly the factors common to agents that depress thyroid function via the pituitary gland. The present data make such a supposition less likely since a number of the dihydroxybenzoic acids that were found to depress "131 release from the rat thyroid (Table IV) neither raise the oxygen consumption in intact rats (32) nor uncouple 
* Variation of the release rate of control rats is in part caused by different feeding periods on the low iodine diets.
Since each animal is its own control this error is eliminated.
t Low iodine diet supplemented with Purina Lab Chow. All other rats pretreated with low iodine diet alone.
$ A change in half-life of under 10 per cent would not be detected by this technique.
oxidative phosphorylation at concentrations in excess of those found in the circulation (24) .2 The observation that pyrogens or an elevated ambient temperature can depress thyroid function 2 Dr. Packer has kindly tested the 2,4-, 2,5-, 2,6-, dihydroxybenzoates and the meta-and parahydroxybenzoic acids in rat heart mitrochondria utilizing a-ketoglutarate, and has found that none of these phenols uncouple oxidative phosphorylation at concentrations as high as 2.5 X 10' M (33) . It should also be pointed out that the uncoupling of thyroxine differs from the two other phenols. All three agents uncouple oxidative phosphorylation in intact mitochondria, but thyroxine fails to uncouple in mitochondria fragmented with digitonin, where dinitrophenol and salicylate are still active (34) . Furthermore, uncoupling induced by thyroxine is sensitive to the concentration of Mg++, whereas that of other phenols is not (35, 36) . in rats as the body temperature is elevated (5) suggested that fever might be a factor in producing thyroid inhibition. However, the production of fever is not required since none of the patients described in the previous paper (1) had temperature elevation. Weight loss, though it can result from treatment with any of these agents and may be associated with a depression in the butanol-extractable iodine of serum (37), appears not to be essential since rats not exhibiting weight loss show similar thyroid depression [ (5) and Table IV] , and the salicylate-treated patients described in the previous paper (1) exhibit thyroid inhibition in the absence of weight (40) , it is in loss. means of de A theory of action that has been proposed for the literature salicylates is that which emphasizes ortho-phenolic thyroid is e3 substitution and the chelation resulting from in-of cortisone ternal hydrogen bonding (17) . Two possible ef-suppress iod fects might be involved: a) replacement of the hy-(50 mg. per drogen by some metal ion required for enzymatic from the gla reactions, and b) stabilization of the carboxylate per day did anion leading to increased acidity, especially in the FurthermorC case of the di-ortho-substituted -y-resorcylate appear to be (38) . The fact that gentisate and -y-resorcylate ance of iodid possess activity would be consistent with this on salicylate formulation as would the inactivity of the m-and required for p-hydroxybenzoic acids (Table IV) . However, the fact tha 3,5-dihydroxybenzoic acid inhibits the release of still occurred 1131 from the gland. Unless one would invoke on constant conversion to an ortho-substituted product, it man treated would seem unlikely that the chelation concept onstrated in can be made to fit the data. The conversion to an 17-ketosteroi active quinonoid intermediate (39) An adrenal mechanism thus appears to be unlikely. Sensitization to the sympathomimetic amines is also not essential, since this is not a characteristic of salicylate-induced hypermetabolism (46) . Lastly, the evidence that both thyroxine and dinitrophenol (47) increase the disappearance rate of exogenous thyrotropin from the circulation does not afford a satisfactory explanation. If this were the reason for the inhibition of thyroid function, histologic evidence of pituitary activation might be expected. This, however, is not the case -both thyroxine and dinitrophenol treatment lead to normal or "inactive" pituitary cytology (5) . Although a temporary rise in pituitary basophils had been reported following salicylate administration to rats (14) , the cell type has not been identified as that characteristic of "thyrotrophs." Furthermore, the rise was not sustained, whereas the thyroid inhibition in man is demonstrable months after the onset of salicylate therapy.
It appears, therefore, that the TSH-inhibiting properties of the thyroid hormones can be mimicked by a number of agents that do not possess thyromimetic activity in many other respects, and that the mechanism of the inhibitory effect remains, at present, obscure. SUMMARY 1. The effect of salicylate on some thyrotropindependent functions of the thyroid gland has been investigated in man and rats.
2. The thyroid of salicylate-treated patients responds to exogenous thyrotropin with an increase in uptake of I131, an elevation of the serum protein bound iodine concentration, and an accelerated rate of release of Il31 from the gland.
3. Salicylate treatment leads-to partial inhibition of goitrogenesis in propylthiouracil-treated rats.
4. Salicylate-C14 does not appear to be significantlyr concentrated in the pituitary gland, hypothalamus, thyroid or adrenal.
5. Salicylate and a variety of its congeners retard the release of I131 from the rat thyroid gland.
6. It is concluded from these findings that the inhibition of thyroid gland function produced by salicylate therapy is mediated via an inhibition of thyrotropic stimulation at a pituitary or higher level. The mechanism of this effect has not been elucidated. It appears not to be related to the uncoupling of oxidative phosphorylation, pyrogenesis, chelating ability of ortho-substituted phenols, or adrenal stimulation.
7. A comparison of some actions of thyroxine, 2,4-dinitrophenol, and salicylate is presented.
